{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:38:02Z","timestamp":1788554282575,"version":"build-2803163510"},"reference-count":132,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Association for Cancer Research IG 2019","award":["23810"],"award-info":[{"award-number":["23810"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Uncontrolled proliferative signals and cell cycle dysregulation due to genomic or functional alterations are important drivers of the expansion of undifferentiated blast cells in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) cells. Therefore, they are largely studied as potential therapeutic targets in the field. We here present the most recent advancements in the evaluation of novel compounds targeting cell cycle proteins or oncogenic mechanisms, including those showing an antiproliferative effect in acute leukemia, independently of the identification of a specific target. Several new kinase inhibitors have been synthesized that showed effectiveness in a nanomolar to micromolar concentration range as inhibitors of FLT3 and its mutant forms, a highly attractive therapeutic target due to its driver role in a significant fraction of AML cases. Moreover, we introduce novel molecules functioning as microtubule-depolymerizing or P53-restoring agents, G-quadruplex-stabilizing molecules and CDK2, CHK1, PI3K\u03b4, STAT5, BRD4 and BRPF1 inhibitors. We here discuss their mechanisms of action, including the downstream intracellular changes induced by in vitro treatment, hematopoietic toxicity, in vivo bio-availability and efficacy in murine xenograft models. The promising activity profile demonstrated by some of these candidates deserves further development towards clinical investigation.<\/jats:p>","DOI":"10.3390\/molecules28031224","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T01:27:58Z","timestamp":1674782878000},"page":"1224","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Targeting Proliferation Signals and the Cell Cycle Machinery in Acute Leukemias: Novel Molecules on the Horizon"],"prefix":"10.3390","volume":"28","author":[{"given":"Andrea","family":"Ghelli Luserna di Ror\u00e0","sequence":"first","affiliation":[{"name":"Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d, Via Piero Maroncelli 40, 47014 Meldola, Italy"},{"name":"Fondazione Pisana per Scienza ONLUS, 56017 San Giuliano Terme, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5774-7362","authenticated-orcid":false,"given":"Mouna","family":"Jandoubi","sequence":"additional","affiliation":[{"name":"Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d, Via Piero Maroncelli 40, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1025-4210","authenticated-orcid":false,"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[{"name":"Scientific Directorate, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d, Via Piero Maroncelli 40, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6954-969X","authenticated-orcid":false,"given":"Giorgia","family":"Simonetti","sequence":"additional","affiliation":[{"name":"Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d, Via Piero Maroncelli 40, 47014 Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: New dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Knight, T.E., Edwards, H., Meshinchi, S., Taub, J.W., and Ge, Y. (2022). \u201cFLipping\u201d the story: FLT3-mutated acute myeloid leukemia and the evolving role of FLT3 inhibitors. Cancers, 14.","DOI":"10.3390\/cancers14143398"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1152\/physrev.00029.2018","article-title":"FMS-like tyrosine kinase 3\/FLT3: From basic science to clinical implications","volume":"99","author":"Kazi","year":"2019","journal-title":"Physiol. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1074-7613(01)00220-5","article-title":"Upregulation of Flt3 expression within the bone marrow Lin-Sca1+c-Kit+ stem cell compartment is accompanied by loss of self-renewal capacity","volume":"15","author":"Adolfsson","year":"2001","journal-title":"Immunity"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2010-10-316232","article-title":"FLT3 expression initiates in fully multipotent mouse hematopoietic progenitor cells","volume":"118","author":"Woll","year":"2011","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1074-7613(02)00419-3","article-title":"Key role of Flt3 ligand in regulation of the common lymphoid progenitor but not in maintenance of the hematopoietic stem cell pool","volume":"17","author":"Sitnicka","year":"2002","journal-title":"Immunity"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1084\/jem.20030323","article-title":"Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo","volume":"198","author":"Karsunky","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41417-019-0120-z","article-title":"The mutational spectrum of FLT3 gene in acute lymphoblastic leukemia is different from acute myeloid leukemia","volume":"27","author":"Zhang","year":"2020","journal-title":"Cancer Gene Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/sj.onc.1205332","article-title":"Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain","volume":"21","author":"Kiyoi","year":"2002","journal-title":"Oncogene"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/sj.onc.1203354","article-title":"Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines","volume":"19","author":"Hayakawa","year":"2000","journal-title":"Oncogene"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 Recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2007-05-091215","article-title":"Prognostic relevance of FLT3-TKD mutations in AML: The combination matters an analysis of 3082 patients","volume":"111","author":"Bacher","year":"2008","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40164-021-00207-4","article-title":"Profiling of somatic mutations and fusion genes in acute myeloid leukemia patients with FLT3-ITD or FLT3-TKD mutation at diagnosis reveals distinct evolutionary patterns","volume":"10","author":"Guan","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1177\/1947601910396505","article-title":"Antileukemic effects of novel first- and second-generation FLT3 inhibitors: Structure-affinity comparison","volume":"1","author":"Weisberg","year":"2010","journal-title":"Genes Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3 -mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2643-3230.BCD-20-0143","article-title":"Patterns of resistance differ in patients with acute myeloid leukemia treated with type I versus type II FLT3 inhibitors","volume":"2","author":"Alotaibi","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2016-04-711820","article-title":"Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis","volume":"130","author":"Smith","year":"2017","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood.2020007626","article-title":"Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin","volume":"137","author":"Schmalbrock","year":"2021","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/bloodadvances.2021006489","article-title":"Molecular profile of FLT3-mutated Relapsed\/refractory patients with AML in the phase 3 ADMIRAL study of Gilteritinib","volume":"6","author":"Smith","year":"2022","journal-title":"Blood Adv."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.stem.2015.01.017","article-title":"CDK6 levels regulate quiescence exit in human hematopoietic stem cells","volume":"16","author":"Laurenti","year":"2015","journal-title":"Cell Stem Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s12185-016-1984-4","article-title":"Cell cycle regulation of hematopoietic stem or progenitor cells","volume":"103","author":"Hao","year":"2016","journal-title":"Int. J. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1038\/onc.2009.170","article-title":"Mammalian cell-cycle regulation: Several Cdks, numerous cyclins and diverse compensatory mechanisms","volume":"28","author":"Satyanarayana","year":"2009","journal-title":"Oncogene"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.dnarep.2004.03.006","article-title":"Mammalian cell cycle checkpoints: Signalling pathways and their organization in space and time","volume":"3","author":"Lukas","year":"2004","journal-title":"DNA Repair"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev.cellbio.13.1.261","article-title":"Cyclin-dependent kinases: Engines, clocks, and microprocessors","volume":"13","author":"Morgan","year":"2003","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/nrm2510","article-title":"Cyclin-dependent kinases and cell-cycle transitions: Does one fit all?","volume":"9","author":"Hochegger","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Gudmundsson, K.O., and Du, Y. (FEBS J., 2022). Quiescence regulation by normal haematopoietic stem cells and leukaemia stem cells, FEBS J., ahead of print.","DOI":"10.1111\/febs.16472"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0092-8674(04)00300-9","article-title":"Cyclin C\/Cdk3 promotes Rb-dependent G0 exit","volume":"117","author":"Ren","year":"2004","journal-title":"Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/cdd.2015.112","article-title":"An essential role for Ink4 and Cip\/Kip cell-cycle inhibitors in preventing replicative stress","volume":"23","author":"Quereda","year":"2015","journal-title":"Cell Death Differ."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1101\/gad.9.10.1149","article-title":"Inhibitors of mammalian G1 cyclin-dependent kinases","volume":"9","author":"Sherr","year":"1995","journal-title":"Genes Dev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"25863","DOI":"10.1074\/jbc.272.41.25863","article-title":"Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor P27Kip1 with cyclin A-Cdk2 and cyclin D2-Cdk4","volume":"272","author":"Blain","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1747-1028-2-12","article-title":"Cdc25 and Wee1: Analogous opposites?","volume":"2","author":"Perry","year":"2007","journal-title":"Cell Div."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2174\/187152008786847756","article-title":"Cell cycle control by the CDC25 phosphatases","volume":"8","author":"Aressy","year":"2012","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1242\/jcs.03200","article-title":"CHK1 phosphorylates CDC25B during the cell cycle in the absence of DNA damage","volume":"119","author":"Schmitt","year":"2006","journal-title":"J. Cell Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7172","DOI":"10.1073\/pnas.1405663111","article-title":"Phosphatases reverse P53-mediated cell cycle checkpoints","volume":"111","author":"Donehower","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","article-title":"Cell cycle regulation: P53-P21-RB signaling","volume":"29","author":"Engeland","year":"2022","journal-title":"Cell Death Differ."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1006\/bbrc.1997.5938","article-title":"Expression of G1-phase cell cycle genes during hematopoietic lineage","volume":"231","author":"Borriello","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.cell.2004.08.002","article-title":"Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6","volume":"118","author":"Malumbres","year":"2004","journal-title":"Cell"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/leu.2015.353","article-title":"CDK6-mediated repression of CD25 is required for induction and maintenance of Notch1-induced T-Cell acute lymphoblastic leukemia","volume":"30","author":"Jena","year":"2016","journal-title":"Leukemia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.18632\/oncotarget.1541","article-title":"CDK6 and P16INK4A in lymphoid malignancies","volume":"4","author":"Kollmann","year":"2013","journal-title":"Oncotarget"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2014-02-558114","article-title":"Requirement for CDK6 in MLL-rearranged acute myeloid leukemia","volume":"124","author":"Placke","year":"2014","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/blood-2007-02-071266","article-title":"Pharmacologic inhibition of CDK4\/6: Mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia","volume":"110","author":"Wang","year":"2007","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood.V86.2.755.bloodjournal862755","article-title":"Analysis of a family of cyclin-dependent kinase inhibitors: P15\/MTS2\/INK4B, P16\/MTS1\/INK4A, and P18 genes in acute lymphoblastic leukemia of childhood","volume":"86","author":"Takeuchi","year":"1995","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.3389\/fonc.2022.916682","article-title":"Cyclin-dependent kinase inhibitors in malignant hematopoiesis","volume":"12","author":"Schirripa","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"6688","DOI":"10.1073\/pnas.0602030103","article-title":"Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia","volume":"103","author":"Williams","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.3324\/haematol.13044","article-title":"Transcriptional upregulation of P21\/WAF\/Cip1 in myeloid leukemic blasts expressing AML1-ETO","volume":"93","author":"Berg","year":"2008","journal-title":"Haematologica"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/sj.leu.2401640","article-title":"Prognostic significance of the cell cycle inhibitor P27Kip1 in acute myeloid leukemia","volume":"14","author":"Yokozawa","year":"2000","journal-title":"Leukemia"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/cncr.31837","article-title":"Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery","volume":"125","author":"Simonetti","year":"2019","journal-title":"Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/bloodadvances.2018028480","article-title":"Complex karyotype AML displays G2\/M signature and hypersensitivity to PLK1 inhibition","volume":"3","author":"Moison","year":"2019","journal-title":"Blood Adv."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ijc.31718","article-title":"Aneuploidy: Cancer strength or vulnerability?","volume":"144","author":"Simonetti","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13046-022-02363-9","article-title":"CDC20 in and out of mitosis: A prognostic factor and therapeutic target in hematological malignancies","volume":"41","author":"Bruno","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Kim, H.J., Ryu, H., Song, J.Y., Hwang, S.G., Jalde, S.S., Choi, H.K., and Ahn, J. (2020). Discovery of oxazol-2-amine derivatives as potent novel FLT3 inhibitors. Molecules, 25.","DOI":"10.3390\/molecules25215154"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"126630","DOI":"10.1016\/j.bmcl.2019.126630","article-title":"Design, synthesis, and biological evaluation of 4-((6,7-dimethoxyquinoline-4-Yl)oxy)aniline derivatives as FLT3 inhibitors for the treatment of acute myeloid leukemia","volume":"29","author":"Xu","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"113215","DOI":"10.1016\/j.ejmech.2021.113215","article-title":"Discovery of novel 4-azaaryl-N-phenylpyrimidin-2-amine derivatives as potent and selective FLT3 inhibitors for acute myeloid leukaemia with FLT3 mutations","volume":"213","author":"Long","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1021\/acsmedchemlett.6b00468","article-title":"Identification of new FLT3 inhibitors that potently inhibit AML cell lines via an azo click-it\/staple-it approach","volume":"8","author":"Ma","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.4155\/fmc-2017-0067","article-title":"Aminoisoquinoline benzamides, FLT3 and Src-family kinase inhibitors, potently inhibit proliferation of acute myeloid leukemia cell lines","volume":"9","author":"Larocque","year":"2017","journal-title":"Future Med. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1021\/acs.jmedchem.1c02079","article-title":"Identification of the benzoimidazole compound as a selective FLT3 inhibitor by cell-based high-throughput screening of a diversity library","volume":"65","author":"Tian","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1038\/s41598-018-21839-3","article-title":"Rational design, synthesis and biological evaluation of pyrimidine-4,6-diamine derivatives as type-II inhibitors of FLT3 selective against c-KIT","volume":"8","author":"Bharate","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.bmcl.2018.06.026","article-title":"Synthesis and characterization of amino acid substituted sunitinib analogues for the treatment of AML","volume":"28","author":"Nemes","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"111710","DOI":"10.1016\/j.ejmech.2019.111710","article-title":"Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases","volume":"184","author":"Baska","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"112232","DOI":"10.1016\/j.ejmech.2020.112232","article-title":"A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia","volume":"193","author":"Sellmer","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1021\/acs.jmedchem.0c02247","article-title":"Discovery of a potent and selective FLT3 inhibitor (Z)- N-(5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-4-methyl-1 H-pyrrol-3-Yl)-3-(pyrrolidin-1-Yl)propanamide with improved drug-like properties and superior efficacy in FLT3-ITD-positive acute myeloid leu","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"113776","DOI":"10.1016\/j.ejmech.2021.113776","article-title":"Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor","volume":"225","author":"Zhang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1021\/acs.jmedchem.1c01792","article-title":"Identification of 2-aminopyrimidine derivatives as FLT3 kinase inhibitors with high selectivity over c-KIT","volume":"65","author":"Tong","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Zhi, Y., Wang, Z., Yao, C., Li, B., Heng, H., Cai, J., Xiang, L., Wang, Y., Lu, T., and Lu, S. (2019). Design and synthesis of 4-(heterocyclic substituted amino)-1h-pyrazole-3-carboxamide derivatives and their potent activity against acute myeloid leukemia (AML). Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20225739"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1021\/acs.jmedchem.8b01594","article-title":"Discovery of N-(4-(6-acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a potent FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutant selective inhibitor for acute myeloid leukemia","volume":"62","author":"Liang","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1021\/acs.jmedchem.9b00223","article-title":"Identification of pyrrolo[2,3-d]pyrimidine-based derivatives as potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3) inhibitors for treating acute myelogenous leukemia","volume":"62","author":"Yuan","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"823","DOI":"10.4155\/fmc-2017-0298","article-title":"Dual FLT3\/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines","volume":"10","author":"Dayal","year":"2018","journal-title":"Future Med. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"10981","DOI":"10.1021\/acs.jmedchem.1c00330","article-title":"3 H-pyrazolo[4,3- f]quinoline-based kinase inhibitors inhibit the proliferation of acute myeloid leukemia cells in vivo","volume":"64","author":"Dayal","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"154061","DOI":"10.1016\/j.phymed.2022.154061","article-title":"O-methylated flavonol as a multi-kinase inhibitor of leukemogenic kinases exhibits a potential treatment for acute myeloid leukemia","volume":"100","author":"Yen","year":"2022","journal-title":"Phytomedicine"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/acs.jnatprod.0c00589","article-title":"Investigation of selected flavonoid derivatives as potent FLT3 inhibitors for the potential treatment of acute myeloid leukemia","volume":"84","author":"Yen","year":"2021","journal-title":"J. Nat. Prod."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1021\/acs.jnatprod.9b00468","article-title":"Semisynthetic derivatives of fradcarbazole A and their cytotoxicity against acute myeloid leukemia cell lines","volume":"82","author":"Li","year":"2019","journal-title":"J. Nat. Prod."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"14664","DOI":"10.1021\/acs.jmedchem.1c01196","article-title":"Discovery of a potent FLT3 inhibitor (LT-850-166) with the capacity of overcoming a variety of FLT3 mutations","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"105669","DOI":"10.1016\/j.bioorg.2022.105669","article-title":"Synthesis and biological evaluation of 6-(pyrimidin-4-Yl)-1H-pyrazolo[4,3-b]pyridine derivatives as novel dual FLT3\/CDK4 inhibitors","volume":"121","author":"Li","year":"2022","journal-title":"Bioorg. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1021\/acs.jmedchem.7b01261","article-title":"Discovery of 4-((7H-pyrrolo[2,3-d]pyrimidin-4-Yl)amino)-N-(4-((4-methylpiperazin-1-Yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-kinase inhibitor with potentially high efficiency against acute myelocytic leukemia","volume":"61","author":"Wang","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"105752","DOI":"10.1016\/j.bioorg.2022.105752","article-title":"Design, synthesis, and biological evaluation of novel pyrido-dipyrimidines as dual topoisomerase II\/FLT3 inhibitors in leukemia cells","volume":"122","author":"Abdelgawad","year":"2022","journal-title":"Bioorg. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.ejmech.2017.08.006","article-title":"Dual inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia","volume":"139","author":"Diab","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood-2018-02-834895","article-title":"Tyrosine kinase inhibitor\u2014Induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors","volume":"132","author":"Maifrede","year":"2018","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-022-01228-0","article-title":"Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies","volume":"15","author":"Padella","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"33410","DOI":"10.18632\/oncotarget.5418","article-title":"T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia","volume":"6","author":"Alachkar","year":"2015","journal-title":"Oncotarget"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1021\/acs.jnatprod.0c00516","article-title":"Biological evaluation of selected flavonoids as inhibitors of MNKs targeting acute myeloid leukemia","volume":"83","author":"Chen","year":"2020","journal-title":"J. Nat. Prod."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.leukres.2007.11.032","article-title":"Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT)","volume":"32","author":"Ozawa","year":"2008","journal-title":"Leuk. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1158\/1535-7163.MCT-13-0561","article-title":"Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK","volume":"13","author":"Vin","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0006-291X(02)02980-7","article-title":"A novel zinc finger protein, ZZaPK, interacts with ZAK and stimulates the ZAK-expressing cells re-entering the cell cycle","volume":"301","author":"Yang","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/leu.2017.257","article-title":"Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia","volume":"32","author":"Reiter","year":"2018","journal-title":"Leukemia"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1476-4598-12-19","article-title":"Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms","volume":"12","author":"Heinrich","year":"2013","journal-title":"Mol. Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ejmech.2019.05.021","article-title":"Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model","volume":"176","author":"Heng","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1124\/mol.110.064642","article-title":"Negative regulatory effects of Mnk kinases in the generation of chemotherapy-induced antileukemic responses","volume":"78","author":"Altman","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"113661","DOI":"10.1016\/j.ejmech.2021.113661","article-title":"Bioisosteric replacements of the indole moiety for the development of a potent and selective PI3K\u03b4 inhibitor: Design, synthesis and biological evaluation","volume":"223","author":"Yang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1021\/acs.jmedchem.7b00369","article-title":"New inhibitor targeting signal transducer and activator of transcription 5 (STAT5) signaling in myeloid leukemias","volume":"60","author":"Juen","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/cmdc.202000841","article-title":"Inhibitors targeting STAT5 signaling in myeloid leukemias: New tetrahydroquinoline derivatives with improved antileukemic potential","volume":"16","author":"Polomski","year":"2021","journal-title":"ChemMedChem"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2000450","DOI":"10.1002\/ardp.202000450","article-title":"Design, synthesis, and antiproliferative effect of 2,9-bis[4-(pyridinylalkylaminomethyl)phenyl]-1,10-phenanthroline derivatives on human leukemic cells by targeting G-quadruplex","volume":"354","author":"Guillon","year":"2021","journal-title":"Arch. Pharm."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"104264","DOI":"10.1016\/j.bioorg.2020.104264","article-title":"Drug-like Biimidazole Derivatives Dually Target c-MYC\/BCL-2 G-Quadruplexes and Inhibit Acute Myeloid Leukemia","volume":"104","author":"Hu","year":"2020","journal-title":"Bioorg. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.bmc.2019.02.041","article-title":"Design and synthesis of various quinizarin derivatives as potential anticancer agents in acute T lymphoblastic leukemia","volume":"27","author":"Hu","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"104849","DOI":"10.1016\/j.bioorg.2021.104849","article-title":"Design, synthesis, and biological activity evaluation of a series of novel sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia","volume":"111","author":"Feng","year":"2021","journal-title":"Bioorg. Chem."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bioorg.2019.01.034","article-title":"3-hydroxyisoindolin-1-one derivates: Synthesis by palladium-catalyzed C\u2013H activation as BRD4 inhibitors against human acute myeloid leukemia (AML) cells","volume":"86","author":"Chen","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1021\/acs.jmedchem.6b01583","article-title":"Design of a biased potent small molecule inhibitor of the bromodomain and PHD finger-containing (Brpf) proteins suitable for cellular and in vivo studies","volume":"60","author":"Igoe","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/blood-2006-05-024018","article-title":"Activation mechanisms of STAT5 by oncogenic Flt3-ITD","volume":"110","author":"Choudhary","year":"2007","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1182\/blood-2009-06-227603","article-title":"Modeling the functional heterogeneity of leukemia stem cells: Role of STAT5 in leukemia stem cell self-renewal","volume":"114","author":"Heuser","year":"2009","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Brachet-Botineau, M., Deynoux, M., Vallet, N., Polomski, M., Juen, L., H\u00e9rault, O., Mazurier, F., Viaud-Massuard, M.C., Pri\u00e9, G., and Gouilleux, F. (2019). A novel inhibitor of Stat5 signaling overcomes chemotherapy resistance in myeloid leukemia cells. Cancers, 11.","DOI":"10.3390\/cancers11122043"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"111550","DOI":"10.1016\/j.biopha.2021.111550","article-title":"G-quadruplex stabilization via small-molecules as a potential anti-cancer strategy","volume":"139","author":"Awadasseid","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1158\/1535-7163.MCT-17-1209","article-title":"APTO-253 stabilizes G-quadruplex DNA, inhibits MYC expression, and induces DNA damage in acute myeloid leukemia cells","volume":"17","author":"Local","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/cmdc.201600511","article-title":"Design, synthesis, and evaluation of 2,9-bis[(substituted-aminomethyl)phenyl]-1,10-phenanthroline derivatives as G-quadruplex ligands","volume":"12","author":"Gueddouda","year":"2017","journal-title":"ChemMedChem"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12185-013-1466-x","article-title":"Bromodomain-PHD finger protein 1 is critical for leukemogenesis associated with MOZ-TIF2 fusion","volume":"99","author":"Shima","year":"2014","journal-title":"Int. J. Hematol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ccell.2018.08.005","article-title":"Mutant NPM1 maintains the leukemic state through HOX expression","volume":"34","author":"Brunetti","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1172\/JCI25546","article-title":"Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations","volume":"116","author":"Dorrance","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"6947","DOI":"10.1158\/0008-5472.CAN-05-4601","article-title":"Gene expression profiling of acute myeloid leukemia with translocation t(8;16)(P11;P13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of Hox gene expression","volume":"66","author":"Esteve","year":"2006","journal-title":"Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4161\/epi.26792","article-title":"Crosstalk between epigenetic readers regulates the MOZ\/MORF HAT complexes","volume":"9","author":"Klein","year":"2014","journal-title":"Epigenetics"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"112338","DOI":"10.1016\/j.ejmech.2020.112338","article-title":"Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6\/8 and bromodomain BRPF1","volume":"200","author":"Ghazy","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"10188","DOI":"10.1021\/acs.jmedchem.7b01447","article-title":"Structure-based design and biological characterization of selective histone deacetylase 8 (HDAC8) inhibitors with anti-neuroblastoma activity","volume":"60","author":"Heimburg","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1021\/acs.jmedchem.5b01478","article-title":"Structure-based design and synthesis of novel inhibitors targeting HDAC8 from schistosoma mansoni for the treatment of schistosomiasis","volume":"59","author":"Heimburg","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.biopha.2018.06.153","article-title":"A novel synthesized 3\u2032 5\u2032-diprenylated chalcone mediates the proliferation of human leukemia cells by regulating apoptosis and autophagy pathways","volume":"106","author":"Zhang","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1080\/14756366.2018.1490734","article-title":"Synthesis and biological evaluation of dithiocarbamate esters of parthenolide as potential anti-acute myelogenous leukaemia agents","volume":"33","author":"Ding","year":"2018","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/cbdd.13159","article-title":"Discovery of novel negletein derivatives as potent anticancer agents for acute myeloid leukemia","volume":"91","author":"Wu","year":"2018","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"23","DOI":"10.18433\/jpps31349","article-title":"Cell cycle arrest and apoptosis induction by a new 2,4- dinitrobenzenesulfonamide derivative in acute leukemia cells","volume":"24","author":"Maioral","year":"2021","journal-title":"J. Pharm. Pharm. Sci."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"127837","DOI":"10.1016\/j.bmcl.2021.127837","article-title":"Synthesis of polyenylpyrrole derivatives with selective growth inhibitory activity against T-Cell acute lymphoblastic leukemia cells","volume":"37","author":"Yoshida","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"111570","DOI":"10.1016\/j.ejmech.2019.111570","article-title":"Synthesis and evaluation of 2-carboxy indole derivatives as potent and selective antileukemic agents","volume":"181","author":"Cury","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"6439","DOI":"10.1038\/s41598-019-42917-0","article-title":"Semisynthetic aurones inhibit tubulin polymerization at the colchicine-binding site and repress PC-3 tumor xenografts in nude Mice and Myc-induced T-ALL in zebrafish","volume":"9","author":"Xie","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41589-021-00742-5","article-title":"Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy","volume":"17","author":"Wang","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/cmdc.202000882","article-title":"Design, synthesis, and biological evaluation of orally bioavailable CHK1 inhibitors active against acute myeloid leukemia","volume":"16","author":"Jin","year":"2021","journal-title":"ChemMedChem"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s43440-019-00004-1","article-title":"Effect of new olivacine derivatives on P53 protein level","volume":"72","author":"Wiatrak","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Simonetti, G., Boga, C., Durante, J., Micheletti, G., Telese, D., Caruana, P., Di Ror\u00e0, A.G.L., Mantellini, F., Bruno, S., and Martinelli, G. (2021). Synthesis of novel tryptamine derivatives and their biological activity as antitumor agents. Molecules, 26.","DOI":"10.3390\/molecules26030683"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/nature13660","article-title":"Synergistic blockade of mitotic exit by two chemical inhibitors of the APC\/C","volume":"514","author":"Sackton","year":"2014","journal-title":"Nature"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000519769","article-title":"Kinase inhibitors and interferons as other myeloid differentiation inducers in leukemia therapy","volume":"145","author":"Takahashi","year":"2022","journal-title":"Acta Haematol."},{"key":"ref_130","first-page":"823","article-title":"New pyridocarbazole derivatives. synthesis and their in vitro anticancer activity","volume":"70","author":"Barowski","year":"2013","journal-title":"Acta Pol. Pharm.-Drug Res."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Hassin, O., and Oren, M. (Nat. Rev. Drug Discov., 2022). Drugging P53 in cancer: One protein, many targets, Nat. Rev. Drug Discov., ahead of print.","DOI":"10.1038\/s41573-022-00571-8"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1158\/0008-5472.CAN-14-2486","article-title":"CDK4\/6 inhibitor PD 0332991 sensitizes acute myeloid leukemia to cytarabine-mediated cytotoxicity","volume":"75","author":"Yang","year":"2015","journal-title":"Cancer Res."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/3\/1224\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:16:37Z","timestamp":1760120197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/3\/1224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,26]]},"references-count":132,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["molecules28031224"],"URL":"https:\/\/doi.org\/10.3390\/molecules28031224","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,26]]}}}